Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push

Executive Summary

NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol

You may also be interested in...



Reimbursement News, In Brief

Sen. Wyden questions Xeljanz pricing at Senate hearing and Sen. Nelson wants new OIG review of Medicaid versus Medicare drug rebates. GAO compares VA, DoD drug purchasing in report.

Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns

Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents

Norvir “March In” Would Deter Future NIH/Industry Collaboration, Bayh Warns

Abbott has the support of one of the authors of the federal technology transfer laws in its fight to prevent the National Institutes of Health from "marching in" on its Norvir patents

Related Content

Latest News
UsernamePublicRestriction

Register

PS041922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel